<DOC>
	<DOCNO>NCT01582516</DOCNO>
	<brief_summary>In Netherlands 2 center investigator-driven phase I/II clinical trial initiate June 2010 test oncolytic adenovirus Delta24-RGD treat glioblastoma patient . The virus administrate use convection-enhanced delivery 4 catheter delivery technique , target solid tumor well infiltrated tumor cell within peri-tumoral brain . Patients enrol cohort 3 per dose-level . The dose level explore : 10^7 , 10^8 , 10^9 , 10^10 , 3*10^10 10^11 viral particle ( vp ) . Once MTD determine , study reach high dose cohort , 6 9 patient enrol MTD evaluate safety preliminary sign efficacy , total least 12 patient receive MTD . The primary objective determine safety tolerability Delta-24-RGD administer CED tumor surround infiltrated brain patient recurrent GBM . Secondary objective determine Progression Free Survival ( PFS ) , Overall Survival ( OS ) , tumor response rate patient recur tumor amenable surgical resection treat MTD . Cerebrospinal fluid well brain interstitial fluid microdialysis next routinely collect sample blood various timepoints , virus infusion . Various neurodegenerative biomarkers well marker immune response assess sample . Furthermore extensive sample PCR analysis perform evaluate distribution shed virus .</brief_summary>
	<brief_title>Safety Study Replication-competent Adenovirus ( Delta-24-rgd ) Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<criteria>1 . Patients histologically proven primary Glioblastoma Multiforme ( GBM ) eligible protocol . 2 . Patients must show unequivocal evidence tumor recurrence progression MRI scan within 3 week prior registration fail prior resection ( surgery biopsy ) and/ chemo and/or radiation therapy . 3 . Recurring tumor must either accessible surgery , , accessible surgery meet follow criterion : 1. unifocal 2. midline shift &lt; 0.5 cm 3. radiological sign uncal herniation 4 . All recur tumor must restrict one hemisphere , without sign subependymal spread . 5 . Before start virus treatment histological analysis resect , biopsied tumor recurrence must confirm diagnosis GBM ( base frozen section ) . 6 . Patients may may prior chemotherapy . 7 . Patients must able read understand inform consent document must sign date inform consent . Procedures obtain informed consent accord ICHGCP , local regulatory requirement rule follow institute . 8 . Patients must &gt; 18 &lt; 75 year old . 9 . Patients must Karnofsky performance status rating &gt; 70 ( Appendix 2 ) . 10 . Patients must recover toxic effect prior therapy . For example , must least two week vincristine , 6 week nitrosoureas , 3 week procarbazine temozolomide administration , 6 week radiation therapy . 11 . If sexually active , patient must willing use barrier contraception duration study . 12 . Patients must adequate hepatic , renal bone marrow function , define absolute neutrophil count ( ANC ) &gt; 1,5* 109/L platelet count &gt; 100* 109/L ALT ( SGPT ) , AST ( SGOT ) Alkaline Phosphatase &lt; 2 time ULN total bilirubin &lt; 1.5 mg/dL creatinine &lt; 1.5 time ULN urea ( BUN ) &lt; 1.5 time ULN 1 . Patients active uncontrolled infection . Upper pulmonary infection flulike sign presence adenovirus preoperative throatswab serum sample determine PCR . All patient must afebrile ( &lt; 38.0 C ) start therapy 2 . Evidence bleed diathesis use anticoagulant medication . 3 . Patients systemic disease unstable condition may associate unacceptable anesthetic/ operative risk and/or would allow safe completion study protocol , e.g . uncontrolled seizure . 4 . Because potential risk recombinant virus contain gene involve cellular growth regulation differentiation could potentially affect develop fetus grow infant , female pregnant , risk pregnancy , breast feeding baby study period exclude . 5 . Because potential risk serious infection immunecompromised individual , patient know HIV infection exclude . 6 . Patients know germline deficit retinoblastoma gene related pathway . 7 . Patients primary malignancy GBM . However , patient curatively treat carcinomain situ basal cell carcinoma patient disease free least 2 year use anticancer therapy , eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>brain tumor</keyword>
	<keyword>virotherapy</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>replication competent adenovirus</keyword>
</DOC>